(MENAFN- ProactiveInvestors - N.America) RXi Pharmaceuticals Corp (NASDAQ:RXII) told investors it has fortified its patent portfolio for its novel RNAi gene therapies.
The company said that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) regarding the composition of matter and methods of use for its self-delivering RNAi compounds targeting connective tissue growth factor (CTGF).
The patent includes RXi's lead clinical candidate called RXI-109 which is currently being evaluated in multiple clinical trials.
Once issued the patent will last until 2031.
Dr Geert Cauwenbergh chief executive said: "We are pleased to have be granted this Notice of Allowance from the USPTO.
"This patent protection for our novel self-delivering RNAi technology further strengthens our position to generate business and commercial development opportunities in the areas of dermal and ocular scarring as well as other fibrotic indications such as liver fibrosis."
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.